Healthy adults
Conditions
Sponsors
Hokkaido Information University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Subjects who agree to participate in this study with a written informed consent. 2. Subjects whose PTX3 is relatively high. 3. Subjects whose L/H is relatively high.
Exclusion criteria
Exclusion criteria: 1. Subjects with difficulty measuring flow- mediated dilation. 2. Subjects who are under physician's advice, treatment, and/or medication for hypertension, dyslipidemia and/or diabetes. 3. Subjects who have a history of bronchial disease (ex. asthma, tuberculosis, pleurisy). 4. Subjects with implantable electronic medical devices. 5. Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, and/or affected with infectious diseases requiring reports to the authorities. 6. Subjects with major surgical history relevant to the digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc. 7. Subjects with unusually high and/or low blood pressure and/or abnormal hematological data. 8. Subjects with severe anemia. 9. Pre- or post-menopausal women complaining of obvious physical changes. 10. Subjects who are at risk of having allergic reactions to drugs or foods especially based on milk. 11. Subjects who used antibiotics within 12 wks, prior to this study. 12. Subjects who regularly use gastrointestinal drugs. 13. Subjects who cannot abstain from taking yoghurt, lactic acid bacteria drink, functional foods which would affect bowl movement during this study. 14. Smokers, alcohol addicts or subjects with disordered lifestyle. 15. Subjects who donated either 400 ml whole blood within 16 wks (women), 12 wks (men), 200 ml whole blood within 4 wks, or blood components within 2 wks, prior to this study. 16. Pregnant or lactating women or women who expect to be pregnant during this study. 17. Subjects who currently participate in other clinical trials, or participated within the last 4 wks prior to this study. 18. Any other medical and/or health reasons unfavorable to participation in the current study, as judged by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Flow-mediated dilation after 12 weeks of ingestion. | — |
Secondary
| Measure | Time frame |
|---|---|
| Flow-mediated dilation after 8 weeks of ingestion, intestinal flora, adiponectin, PAI-1, hsCRP, GLP-1, serum glucose level, TMAO, PTX3, blood inflammatory marker, heart rate variability, electroencephalogram during sleeping, sleeping record, survey on subjects' sleeping and mental and physical conditions. | — |
Countries
Japan
Contacts
Public ContactNaoyuki HONMA
Hokkaido Information University Health Information Science Center
Outcome results
None listed